Company
Uni-Bio Science is a Hong Kong-listed biopharmaceutical firm focused on regenerative therapeutics for dermatology, orthopaedics, and ophthalmology. It owns three GMP production bases with full R&D, manufacturing, and commercial capabilities, delivering solid financial growth in 2025. Led by Chairman Kingsley Leung, the veteran management team covers finance, R&D, production, and global commercialisation. The Group operates multi-channel domestic sales networks and advances global expansion via overseas licensing and FDA applications of core drugs.
Description
Uni-Bio Science is a Hong Kong-listed biopharmaceutical company specialising in regenerative therapies for dermatology, orthopaedics, and ophthalmology. It owns three GMP manufacturing sites in Beijing, Shenzhen, and Dongguan, with integrated full-chain capabilities of R&D, production, and commercialisation. The Group recorded HK$586 million revenue in 2025, with double-digit CAGRs of key financial metrics from 2023 to 2025. It operates diversified domestic channels including hospitals, e-commerce, retail pharmacies, and medical aesthetics, while expanding globally via product out-licensing for teriparatide and ongoing FDA filing of core product UNI-PTH to tap international regenerative medicine markets.
